NCT02439346View on ClinicalTrials.gov

Phase I Dose Escalation and Expansion of Oral BAY 1143269 in Combination With Intravenous Docetaxel

PHASE1TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

June 15, 2015

Primary Completion Date

March 27, 2017

Study Completion Date

April 24, 2017

Conditions
Medical Oncology
Interventions
DRUG

BAY1143269 tablet

BAY 1143269 5 mg or 25 mg tablet. Each treatment cycle will last 21 days.

Trial Locations (4)

75246

Dallas

77030

Houston

78229

San Antonio

SM2 5PT

Sutton

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT02439346 - Phase I Dose Escalation and Expansion of Oral BAY 1143269 in Combination With Intravenous Docetaxel | Biotech Hunter | Biotech Hunter